Literature DB >> 9403956

Bayes estimates for immunological progression rates in HIV disease.

A J McNeil1.   

Abstract

We develop Bayesian methods for calculating shrinkage estimates of immunological progression rates (for example, CD4 count decline rates) in populations of HIV-infected patients. These methods make the assumption that decline of immunological markers may be modelled as approximately linear on some suitable chosen scale. They are applicable in situations where seroconversion times are unknown and follow-up of patients is variable, with some patients having only sparse measurements of immunological markers. Fitting of models is achieved by Gibbs sampling and CD4 count data from 603 members of the Edinburgh City Hospital Cohort with at least two CD4 determinations are analysed to provide an illustration. It is found that Bayesian shrinkage estimates for CD4 slopes on the square root scale are much more effective predictors of future CD4 counts than the least squares estimates, with respect to squared error loss. Of various shrinkage estimators considered, the most effective corresponds to the simplest model, which can also be fitted using SAS. A characterization of the pattern of CD4 loss in the Edinburgh cohort is obtained (mean rate of decline on root scale-1.61 per annum, standard deviation 1.03) and the effect of various covariates (sex, age, risk category and HLA antigen type) on immunological progression is considered. It is found that homosexual men in Edinburgh and patients with HLA haplotype A1B8DR3 experience significantly faster loss of CD4.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403956     DOI: 10.1002/(sici)1097-0258(19971130)16:22<2555::aid-sim690>3.0.co;2-y

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Interferon regulatory factor 1 polymorphisms previously associated with reduced HIV susceptibility have no effect on HIV disease progression.

Authors:  Aida Sivro; Lyle R McKinnon; Hezhao Ji; Joshua Kimani; Walter Jaoko; Francis A Plummer; Ruey-Chyi Su; T Blake Ball
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

2.  Development and validation of decision rules to guide frequency of monitoring CD4 cell count in HIV-1 infection before starting antiretroviral therapy.

Authors:  Thierry Buclin; Amalio Telenti; Rafael Perera; Chantal Csajka; Hansjakob Furrer; Jeffrey K Aronson; Paul P Glasziou
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

Review 3.  Effect of Opioid Use on Immune Activation and HIV Persistence on ART.

Authors:  Livio Azzoni; David Metzger; Luis J Montaner
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-25       Impact factor: 7.285

4.  Injecting drug use is associated with a more rapid CD4 cell decline among treatment naïve HIV-positive patients in Indonesia.

Authors:  Hinta Meijerink; Rudi Wisaksana; Shelly Iskandar; Martin den Heijer; Andre J A M van der Ven; Bachti Alisjahbana; Reinout van Crevel
Journal:  J Int AIDS Soc       Date:  2014-01-03       Impact factor: 5.396

5.  The impact of monitoring HIV patients prior to treatment in resource-poor settings: insights from mathematical modelling.

Authors:  Timothy B Hallett; Simon Gregson; Sabada Dube; Geoff P Garnett
Journal:  PLoS Med       Date:  2008-03-11       Impact factor: 11.069

6.  Late entry to HIV care limits the impact of anti-retroviral therapy in The Netherlands.

Authors:  Colette Smit; Timothy B Hallett; Joep Lange; Geoff Garnett; Frank de Wolf
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.